AIM
MRVI icon

Artemis Investment Management’s Maravai LifeSciences MRVI Stock Holding History

Artemis Investment Management’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,476,728
Closed -$63.3M – 248
2022
Q3 		$63.3M Buy
2,476,728
+242,162
+11% +$6.08M 0.72% 51
2022
Q2 		$63.6M Buy
2,234,566
+918,958
+70% +$29.1M 0.65% 51
2022
Q1 		$46.3M Buy
1,315,608
+112,878
+9% +$3.78M 0.37% 80
2021
Q4 		$50.4M Buy
1,202,730
+926,730
+336% +$37.5M 0.37% 91
2021
Q3 		$13.5M Buy
+276,000
New +$13.5M 0.11% 172

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
OCBV
Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Artemis Investment Management's MRVI Position: Q4 2022 in Review

Artemis Investment Management sold out of Maravai LifeSciences (MRVI) in Q4 2022, closing a stake of 2,476,728 shares — an estimated $63.3M sold.

Artemis Investment Management first reported a position in MRVI in Q3 2021 and held it in 5 quarters. The position peaked at $63.6M in Q2 2022. 212 funds tracked by Wall St. Rank hold MRVI as of Q4 2022.

  • Artemis Investment Management reported no remaining Maravai LifeSciences position as of Q4 2022 after selling out during the quarter.
  • Artemis Investment Management sold 2,476,728 Maravai LifeSciences shares in Q4 2022, an estimated $63.3M.
  • Artemis Investment Management first reported a position in Maravai LifeSciences in Q3 2021 and held it in 5 quarters.
  • Artemis Investment Management's Maravai LifeSciences position peaked at $63.6M in Q2 2022.
  • 212 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2022.

Based on Artemis Investment Management's 13F filing for Q4 2022, filed 25 Jan 2023.